Multiple mechanisms involved in obesity-induced hypertension

Heart Lung and Circulation

Volumn 12, Issue 2, 2003, Pages 84-93

  Antic, Vladan ^a   Dulloo, Abdul ^a   Montani, Jean Pierre ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Hypertension; Insulin resistance; Leptin; Obesity; Sympathetic

Indexed keywords

FATTY ACID; INSULIN; LEPTIN;

ADRENERGIC STIMULATION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOTHELIUM; HEART FUNCTION; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY TUBULE ABSORPTION; LIPID STORAGE; MORBID OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SODIUM ABSORPTION; SODIUM BALANCE; SODIUM RETENTION; VASCULAR DISEASE; VASOCONSTRICTION; WEIGHT GAIN;

EID: 0142061107     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-2892.2003.00200.x     Document Type: Article

References (102)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.
2. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int. J. Obes. Relat. Metab. Disord. 2002; 26: S28-38.
3. Bjorntorp P. Obesity. Lancet 1997; 350: 423-6.
4. Frankish H. Obesity and diabetes epidemics show no sign of abating. Lancet 2001; 358: 896.
5. Magarey AM, Daniels LA, Boulton TJ. Prevalence of overweight and obesity in Australian children and adolescents: reassessment of 1985 and 1995 data against new standard international definitions. Med. J. Aust. 2001; 174: 561-4.
6. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a 'no-salt' culture. Circulation 1975; 52: 146-51.
7. Truswell AS, Kennelly BM, Hansen JD, Lee RB. Blood pressures of Kung bushmen in Northern Botswana. Am. Heart J. 1972; 84: 5-12.
8. Pavan L, Casiglia E, Braga LM et al. Effects of a traditional lifestyle on the cardiovascular risk profile: the Amondava population of the Brazilian Amazon. Comparison with matched African, Italian and Polish populations. J. Hypertens. 1999; 17: 749-56.
9. Gracey M. New World syndrome in Western Australian aborigines. Clin. Exp. Pharmacol. Physiol. 1995; 22: 220-25.
10. Larimore JW. A study of blood pressure in relation to type of bodily habitus. Arch. Intern. Med. 1923; 31: 567-72.
11. Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J. Hypertens. 1994; 12: 1433-7.
12. Hall JE. Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994; 23: 381-94.
13. Rocchini AP, Moorehead C, Wentz E, DeRemer S. Obesity-induced hypertension in the dog. Hypertension 1987; 9: III64-8.
14. Hall JE, Brands MW, Dixon WN, Smith MJ Jr. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 1993; 22: 292-9.
15. Mizelle HL, Edwards TC, Montani JP. Abnormal cardiovascular responses to exercise during the development of obesity in dogs. Am. J. Hypertens. 1994; 7: 374-8.
16. Carroll JF, Dwyer TM, Grady AW et al. Hypertension, cardiac hypertrophy, and neurohumoral activity in a new animal model of obesity. Am. J. Physiol. 1996; 271: H373-8.
17. Carroll JF, Summers RL, Dzielak DJ, Cockrell K, Montani JP, Mizelle HL. Diastolic compliance is reduced in obese rabbits. Hypertension 1999; 33: 811-15.
18. Antic V, Tempini A, Montani JP. Serial changes in cardiovascular and renal function of rabbits ingesting a high-fat, high-calorie diet. Am. J. Hypertens. 1999; 12: 826-9.
19. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96: 3423-9.
20. Grassi G, Seravalle G, Cattaneo BM et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560-63.
21. Sowers JR, Nyby M, Stern N et al. Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension 1982; 4: 686-91.
22. Tuck ML, Sowers JR, Dornfeld L, Whitfield L, Maxwell M. Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinol. (Copenh.) 1983; 102: 252-7.
23. Young JB, Macdonald IA. Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int. J. Obes. Relat. Metab. Disord. 1992; 16: 959-67.
24. Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992; 19: I67-77.
25. Landsberg L, Young JB. Fasting, feeding and regulation of the sympathetic nervous system. N. Engl. J. Med. 1978; 298: 1295-301.
26. Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation 1994; 89: 2634-40.
27. Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 1999; 33: 548-53.
28. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995; 25: 893-7.
29. Antic V, Kiener-Belforti F, Tempini A, Van Vliet BN, Montani JP. Role of the sympathetic nervous system during the development of obesity-induced hypertension in rabbits. Am. J. Hypertens. 2000; 13: 556-9.
30. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am. J. Hypertens. 2001; 14: 694-8.
31. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996; 334: 292-5.
32. Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999; 33: 542-7.
33. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 1997; 30: 619-23.
34. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409-14.
35. Aizawa-Abe M, Ogawa Y, Masuzaki H et al. Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest. 2000; 105: 1243-52.
36. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48: 903-8.
37. Lembo G, Vecchione C, Fratta L et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-7.
38. Arch JR, Stock MJ, Trayhurn P. Leptin resistance in obese humans: does it exist and what does it mean? Int. J. Obes. Relat. Metab. Disord. 1998; 22: 1159-63.
39. Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51: 439-42.
40. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J. Hypertens. 1999; 17: 1949-53.
41. Stepniakowski KT, Goodfriend TL, Egan BM. Fatty acids enhance vascular alpha-adrenergic sensitivity. Hypertension 1995; 25: 774-8.
42. Weiss B, Maickel RP. Sympathetic nervous control of adipose tissue lipolysis. Int. J. Neuropharmacol. 1968; 7: 395-403.
43. Smith U. Adrenergic control of human adipose tissue lipolysis. Eur. J. Clin. Invest. 1980; 10: 343-4.
44. Collins S, Surwit RS. The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Prog. Horm. Res. 2001; 56: 309-28.
45. Steffens AB, Van der Gugten J, Godeke J, Luiten PG, Strubbe JH. Meal-induced increases in parasympathetic and sympathetic activity elicit simultaneous rises in plasma insulin and free fatty acids. Physiol. Behav. 1986; 37: 119-22.
46. Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension 1995; 26: 764-70.
47. Steinberg HO, Tarshoby M, Monestel R et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest. 1997; 100: 1230-39.
48. Stepniakowski KT, Sallee FR, Goodfriend TL, Zhang Z, Egan BM. Fatty acids enhance neurovascular reflex responses by effects on alpha 1-adrenoceptors. Am. J. Physiol. 1996; 270: R1340-46.
49. Grekin RJ, Vollmer AP, Sider RS. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension 1995; 26: 193-8.
50. Grekin RJ, Dumont CJ, Vollmer AP, Watts SW, Webb RC. Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. Am. J. Physiol. 1997; 273: R324-30.
51. Stout RW. Insulin and atheroma - an update. Lancet 1987; 1: 1077-9.
52. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1966; 1: 1336-7.
53. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N. Engl. J. Med. 1987; 317: 350-57.
54. Ferrannini E, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J. Cardiovasc. Pharmacol. 1990; 15: S18-25.
55. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q. J. Med. 1986; 61: 1081-90.
56. Vollenweider P, Tappy L, Randin D et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J. Clin. Invest. 1993; 92: 147-54.
57. Ferrari P, Weidmann P. Insulin, insulin sensitivity and hypertension. J. Hypertens. 1990; 8: 491-500.
58. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J. Clin. Invest. 1975; 55: 845-55.
59. Rocchini AP, Katch V, Schork A, Kelch RP. Insulin and blood pressure during weight loss in obese adolescents. Hypertension 1987; 10: 267-73.
60. Muscelli E, Natali A, Bianchi S et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am. J. Hypertens. 1996; 9: 746-52.
61. Rocchini AP, Katch V, Kveselis D et al. Insulin and renal sodium retention in obese adolescents. Hypertension 1989; 14: 367-74.
62. Scherrer U, Vollenweider P, Randin D, Jequier E, Nicod P, Tappy L. Suppression of insulin-induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation 1993; 88: 388-94.
63. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J. Clin. Invest. 1990; 85: 1844-52.
64. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J. Clin. Invest. 1994; 93: 2365-71.
65. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 1992; 41: 1076-83.
66. Sartori C, Scherrer U. Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation. J. Hypertens. 1999; 17: 1517-25.
67. Hsueh WA, Buchanan TA. Obesity and hypertension. Endocrinol. Metab. Clin. North Am. 1994; 23: 405-27.
68. Shulman GI. Cellular mechanisms of insulin resistance. J. Clin. Invest. 2000; 106: 171-6.
69. Roden M, Price TB, Perseghin G et al. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 1996; 97: 2859-65.
70. Griffin ME, Marcucci MJ, Cline GW et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-74.
71. Schmitz-Peiffer C, Browne CL, Oakes ND et al. Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 1997; 46: 169-78.
72. Long SD, Pekala PH. Regulation of GLUT4 gene expression by arachidonic acid. Evidence for multiple pathways, one of which requires oxidation to prostaglandin E2. J. Biol. Chem. 1996; 271: 1138-44.
73. Zierath JR, Houseknecht KL, Gnudi L, Kahn BB. High-fat feeding impairs insulin-stimulated GLUT4 recruitment via an early insulin-signaling defect. Diabetes 1997; 46: 215-23.
74. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. 1983; 72: 1737-47.
75. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
76. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995; 95: 2409-15.
77. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin. Cell Dev. Biol. 1999; 10: 19-29.
78. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 1993; 268: 26055-8.
79. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl Acad. Sci. USA 1994; 91: 4854-8.
80. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α. Science 1996; 271: 665-8.
81. Kroder G, Bossenmaier B, Kellerer M et al. Tumor necrosis factor-alpha - and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J. Clin. Invest. 1996; 97: 1471-7.
82. Paz K, Hemi R, LeRoith D et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Biol. Chem. 1997; 272: 29911-18.
83. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J. Biol. Chem. 1995; 270: 23780-84.
84. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF- alpha function. Nature 1997; 389: 610-14.
85. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin. Invest. 1994; 94: 1543-9.
86. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-5.
87. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor J. Proc. Natl Acad. Sci. USA 1999; 96: 6902-7.
88. Kim F, Gallis B, Corson MA. TNF-alpha inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am. J. Physiol. Cell Physiol. 2001; 280: C1057-65.
89. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 1993; 328: 1230-35.
90. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772-6.
91. Du ZY, Dusting GJ, Woodman OL. Inhibition of nitric oxide synthase specifically enhances adrenergic vasoconstriction in rabbits. Clin. Exp. Pharmacol. Physiol. 1992; 19: 523-30.
92. Lin MT, Pan SP, Lin JH, Yang YL. Central control of blood pressure by nitrergic mechanisms in organum vasculosum laminae terminalis of rat brain. Br. J. Pharmacol. 1999; 127: 1511-17.
93. Zhang K, Patel KP. Effect of nitric oxide within the paraventricular nucleus on renal sympathetic nerve discharge: role of GABA. Am. J. Physiol. 1998; 275: R728-34.
94. Kishi T, Hirooka Y, Sakai K, Shigematsu H, Shimokawa H, Takeshita A. Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension 2001; 38: 896-901.
95. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 1994; 23: I20-24.
96. Granger JP, West D, Scott J. Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. Hypertension 1994; 23: I8-11.
97. DiBona GF, Kopp UC. Neural control of renal function. Physiol. Rev. 1997; 77: 75-197.
98. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N. Engl. J. Med. 1981; 304: 930-33.
99. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J. Mol. Med. 2001; 79: 21-9.
100. Dessi-Fulgheri P, Sarzani R, Tamburrini P et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypetensive obese patients. J. Hypertens. 1997; 15: 1695-9.
101. Endre T, Mattiasson I, Berglund G, Hulthen UL. Insulin and renal sodium retention in hypertension-prone men. Hypertension 1994; 23: 313-19.
102. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am. J. Hypertens. 1997; 10: 49S-55S.